Impact BioMedical Inc. Common Stock (IBO)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses I can understand, with durable competitive advantages, honest accounting, and a margin of safety. Impact BioMedical fails most of those tests. It has two employees, and its filed figures are almost invisible: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $3,000 and net income was -$699,000. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $7,000 and net income was -$2.3 million. For FY2025, revenue was $32,000 and net loss was $11.8 million; FY2024 had a net loss of $24.7 million and FY2023 a net loss of $4.3 million. The Peter Lynch category is none because it lost money in each of the last four years. That is not a moat; that is a science project with public shares. Financial health is mixed: debt is low at 0.09 debt-to-equity, and FairStock calculates a high Altman Z-score of 89.56, but trailing free cash flow is -$508,000 and return on capital employed is -17.79%. Valuation is the crux. At the 2026-10-13 close of $3.98, market cap is $429.1 million, while FY2025 revenue was only $32,000. FairStock's P/B is 39.80, Graham Number is $1.41, and margin of safety is -182.27%. FairStock also reports P/E 4.52 and EPS $0.88, but those conflict with filed losses and I would not trust them without reconciliation. Growth is not demonstrated: revenue growth is -57.14% and free cash flow yield -0.1%. As a value investor, I see no margin of safety and no proven earning power.

In plain English: Impact BioMedical is a very small healthcare research company with only two employees. It sells almost nothing and loses money, so the business looks weak today. At about $3.98 a share, the price looks high compared with those tiny sales and losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer